medigraphic.com

2014, Number 4

<< Back Next >>

Rev Hematol Mex 2014; 15 (4)

Waldenstrom’s macroglobulinemia: An overview

Morales-Gónzalez A, Santos-Lozano A

Language: Spanish
References: 21
Page: 184-189
PDF size: 411.91 Kb.


ABSTRACT

Waldenstrom’s macroglobulinemia is a type of non-Hodgkin lymphoma of low-grade malignancy and slow progression of lymphocytes B. It is a rare disease that begins with one or more mutations in the DNA of a lymphocyte B. Its cause is unknown, although genetic factors may determine it. While it is incurable, treatment is based on chemotherapy with a single or combined drugs. Currently, ongoing clinical and randomized controlled trials attempt to investigate the safety and efficacy of new therapies and treatments as well being able to control the symptoms of the disease and improve the quality of life of patients.


REFERENCES

  1. Ruiz Argüelles GJ. Fundamentos de Hematología. 4ª ed. Editorial Médica Panamericana, 2009.

  2. Moraleda JM. Hematología: patología médica. 2ª ed. Madrid: Luzán, 1996:153-168.

  3. Ribatti D, Nico B, Ranieri G, Specchia G. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 2013;15:231-238.

  4. Campo E, Swerdlow HS, Harris NL, Pileri S, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2009;117:5019-5032.

  5. Leleu X, Gay J, Roccaro AM, Moreau AS, et al. Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol 2009;82:1-12.

  6. Chen CI. Treatment for Waldenström macroglobulinemia. Ann Oncol 2004;15:550-558.

  7. Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood 2007;109:5096-5103.

  8. Neparidze N, Dhodapkar MV. Waldenström macroglobulinemia: Recent advances in biology and therapy. Clin Adv Hematol Oncol 2009;7:677-681, 687-690.

  9. Ghobrial IM. Choice of therapy for patients with Waldenström macroglobulinemia. J Clin Oncol 2013;31:291-293.

  10. Ghobrial IM, Witzig TE. Waldenström macroglobulinemia. Curr Treat Options Oncol 2004;5:239-247.

  11. Ruiz-Arguelles GJ, Ramirez-Cisneros FJ, Flores-Martinez J, Cernuda-Graham MC. Waldenström macroglobulinemia is infrequent in Mexican mestizos: experience of a hematological diseases referral center. Rev Invest Clin 2000;52:497-499.

  12. HL, AA, IG. Novel treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13:238-240.

  13. Bianchi G SA, Kumar S, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenström macroglobulinemia: current evidence and research. Appl Clin Genet 2013;6:33-42.

  14. IM G. Are you sure this is Waldenström macroglobulinemia? Hematology Am Soc Hematol Educ Program 2012:586-594.

  15. Poulain S RC, Decambron A, Renneville A, Herbaux C, et al. MYD88 L265P mutation in Waldenström macroglobulinemia. Blood 2013;121:4504-4511.

  16. Hunter ZR XL, Yang G, Zhou Y, Liu X, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIMlike CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123:1637-1646.

  17. Hassler MR SA, Egger G. Combating the epigenome: epigenetic drugs against non-Hodgkin’s lymphoma. Epigenomics 2013;5:397-415.

  18. Gertz MA, Fonseca R, Rajkumar SV. Waldentröm macroglobulinemia. The oncologist: Fundamentals of cancer. Medicina 2000;5:63-67.

  19. Leleu X, Roccaro AM, Moreau AS, Dupire S, et al. Waldenström macroglobulinemia. Cancer Lett 2008.

  20. Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobulinemia. Blood 1994;83:1452-1459.

  21. Health NCIaNIo. Diccionario de cáncer EEUU2012 [citado: 2013 febrero 9]. Disponible en: http://www.cancer.gov/ diccionario?CdrID=346513.




2020     |     www.medigraphic.com